Search results - Portal of Medical Data Models (MDM-Portal)

Filter search results
Select data models

Selected data models

You must log in to select data models for download or further analysis.

10 Search results.

End form: Port / CVC VTETumor02 Prophylactic Treatment of Thromboembolism with Enoxaparin EudraCT number: 2007-002036-28 - End form: Port / CVC

- 9/14/16 - 1 form, 1 itemgroup, 8 items, 1 language

Itemgroup: Port Catheters; Central venous catheter

Study documentation part: End form: Port / CVC, VTETumor02. This is a prospective, randomized, controlled, unicentric, open study on prophylactic treatment of thromboembolism with Enoxaparin in non-surgical oncology patients under systemic antineoplastic therapy. Principal Investigator Prof. Dr. Max E. Scheulen, Clinic and Polyclinic for Internal medicine (Tumor research), University Hospital of Essen, Germany. EudraCT number: 2007-002036-28, Version 0.6 vom 06.08.09.

CEC - revascularisation GSK study Chronic Coronary Heart Disease NCT00799903

- 1/11/18 - 1 form, 3 itemgroups, 37 items, 1 language

Itemgroups: CEC - revascularisation, Urgent coronary revascularisation for myocardial ischemia, CEC Status

Study ID: 100601 Clinical Study ID: LPL100601 Study Title: LPL100601, A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00799903 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: darapladib Trade Name: darapladib Study Indication: Atherosclerosis Study part: CEC -revascularisation Repeating form (Scheduled visits)

Investigational product (Liver) GSK study Chronic Coronary Heart Disease NCT00799903

- 1/4/18 - 1 form, 2 itemgroups, 8 items, 1 language

Itemgroups: Liver event during treatment period, Liver event after treatment period

Study ID: 100601 Clinical Study ID: LPL100601 Study Title: LPL100601, A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00799903 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: darapladib Trade Name: darapladib Study Indication: Atherosclerosis Study part: Investigational product (Liver)

Investigational product Repeating form GSK study Chronic Coronary Heart Disease NCT00799903

- 12/22/17 - 1 form, 2 itemgroups, 8 items, 1 language

Itemgroups: Investigational product, Investigational product compliance

Study ID: 100601 Clinical Study ID: LPL100601 Study Title: LPL100601, A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00799903 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: darapladib Trade Name: darapladib Study Indication: Atherosclerosis Study part: Investigational product Repeating form (Scheduled visits)

Concomitant medications Repeating form GSK study Chronic Coronary Heart Disease NCT00799903

- 12/22/17 - 1 form, 1 itemgroup, 13 items, 1 language

Itemgroup: Concomitant medications

Study ID: 100601 Clinical Study ID: LPL100601 Study Title: LPL100601, A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00799903 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: darapladib Trade Name: darapladib Study Indication: Atherosclerosis Study part: Concomitant medications - Repeating form (Scheduled visits)

Investigational product GSK study Chronic Coronary Heart Disease NCT00799903

- 12/22/17 - 1 form, 3 itemgroups, 16 items, 1 language

Itemgroups: Investigational product, Investigational product discontinuation, Post-IP Follow-up status

Study ID: 100601 Clinical Study ID: LPL100601 Study Title: LPL100601, A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00799903 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: darapladib Trade Name: darapladib Study Indication: Atherosclerosis Study part: Investigational product

Standard of care medications GSK study Chronic Coronary Heart Disease NCT00799903

- 12/12/17 - 1 form, 1 itemgroup, 23 items, 1 language

Itemgroup: Standard of care medications

Study ID: 100601 Clinical Study ID: LPL100601 Study Title: LPL100601, A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00799903 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: darapladib Trade Name: darapladib Study Indication: Atherosclerosis Study part: Standard of care medications

Eligibility Pulmonary Hypertension NCT01156636

- 6/10/17 - 1 form, 2 itemgroups, 10 items, 1 language

Itemgroups: Inclusion Criteria, Exclusion Criteria

Phosphodiesterase-5 (PDE5) Inhibition and Pulmonary Hypertension in Diastolic Heart Failure; ODM derived from: https://clinicaltrials.gov/show/NCT01156636

Prescription MS Outpatient Department Neurology University Hospital Essen - Prescription

- 3/27/17 - 1 form, 3 itemgroups, 12 items, 1 language

Itemgroups: Administrative, value, Medication; Antibiotic; Infusion

Documentation form "Verordnung" converted to ODM format. Routine documentation of University Hospital of Essen. Publication granted by: Priv.-Doz. Dr. med. Benedikt, University Hospital of Essen, Essen, Germany.

Q801NWD 16 Verlauf University Hospital Muenster (UKM) Subform

- 11/24/16 - 1 form, 7 itemgroups, 32 items, 1 language

Itemgroups: Diagnostics, Cerebral vascular diagnostics, Therapy/ Secondary prevention, Secondary prevention, Thrombolysis, Beginning of rehabilitation, Complications

Hospital Routine Documentation Subform at the University Hospital Muenster. Original Form name: Q801NWD 16 Verlauf.

Please use this form for feedback, questions and suggestions for improvements.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.